公开(公告)号：US12121444B2

公开(公告)日：2024-10-22

申请号：US18321797

申请日：2023-05-23

申请人： WALDEMAR LINK GMBH & CO. KG

发明人： Eckhard Bauer ,  Helmut D. Link

IPC分类号： A61F2/30 ,  A61F2/02 ,  A61F2/28 ,  A61F2/34

CPC分类号： A61F2/30771 ,  A61F2/34 ,  A61F2002/30784 ,  A61F2002/30838 ,  A61F2002/30884 ,  A61F2002/3093 ,  A61F2002/30985 ,  A61F2250/0067

摘要： Implantable drug-eluting device comprising a microporous structure having regularly arranged pores in at least two different uniform sizes, and manufacturing method. The pores are configured for receiving a drug and are being connected by interconnections. Interconnections originating from pores of a first size have a first elution area and interconnections originating from pores of a second size have a second elution area. The interconnections convey the drug to a surface of the device for elution to surrounding tissue. The ratio between the first and the second elution areas is predefined and selectable. The differently sized elution areas provide for different outflow rates. This allows for simple but reliable dispensing of drugs at positively controlled and well determined rates. Particularly, this enables a single implantable device to dispense drugs over preselectable durations of time, like short-term or long-term.

公开(公告)号：US12096941B2

公开(公告)日：2024-09-24

申请号：US17388327

申请日：2021-07-29

申请人： Tulavi Therapeutics, Inc. ,  INCEPT, LLC

发明人： Corinne Bright ,  Yong Ren ,  Ken Martin ,  Farhad Khosravi ,  Amarpreet S. Sawhney

IPC分类号： A61B17/12 ,  A61F2/00 ,  A61F2/02 ,  A61F2/08 ,  A61L27/52

CPC分类号： A61B17/12181 ,  A61F2/0059 ,  A61F2/02 ,  A61F2/08 ,  A61L27/52

摘要： Disclosed are methods, devices and materials for the in situ formation of an implant for treating a nerve. A treatment site on a nerve is positioned within a cavity defined by a form. A transformable media is introduced into the form cavity to surround the treatment site. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the treatment site. The implant may be a growth inhibiting nerve cap to inhibit neuroma formation following planned or traumatic nerve injury, a growth permissive conduit for facilitating reconnection of a severed nerve, or an anchor for stabilizing a pain management electrode with respect to a nerve. Access to the nerve treatment site may be open surgical or percutaneous.

公开(公告)号：US12090300B2

公开(公告)日：2024-09-17

申请号：US16412281

申请日：2019-05-14

申请人： Giner Life Sciences, Inc.

发明人： Simon G. Stone

IPC分类号： A61F2/02 ,  A61K48/00 ,  A61M5/142 ,  A61M39/02 ,  C25B1/04

CPC分类号： A61M5/14276 ,  A61F2/022 ,  A61K48/0075 ,  C25B1/04 ,  A61M2005/14204 ,  A61M39/0208 ,  A61M2202/0208

摘要： Method and system for controlling oxygen delivery to a cell implant. In one embodiment, the system includes a water electrolyzer, a cell capsule, a gas conduit, a total fluid pressure sensor, and a controller. The water electrolyzer generates gaseous oxygen with a variable output. The cell capsule includes a cell chamber adapted to hold cells. The gas conduit interconnects the water electrolyzer and the cell capsule to deliver gaseous oxygen generated by the water electrolyzer to the cell capsule. The total fluid pressure sensor is positioned at a location that provides a representative reading of the total fluid pressure within the cell chamber. The controller is electrically coupled both to the total fluid pressure sensor and to the water electrolyzer so that the controller may control the variable output of the water electrolyzer based on one or more sensed total pressure readings from the total fluid pressure sensor.

公开(公告)号：US12048617B2

公开(公告)日：2024-07-30

申请号：US17146305

申请日：2021-01-11

申请人： Markman Biologics Corporation

发明人： Barry Markman

IPC分类号： A61F2/02 ,  A61F2/00 ,  A61L27/54

CPC分类号： A61F2/0077 ,  A61F2/0063 ,  A61L27/54 ,  A61F2002/0068 ,  A61F2002/0081 ,  A61F2240/002 ,  A61F2240/005 ,  A61F2250/0026 ,  A61F2250/0048 ,  A61F2250/0051 ,  A61F2250/0067

摘要： In a method of creating a modified tissue graft, at least one exterior surface of a graft is modified by compressing, cutting and/or removing one or more portions thereof, such as to create designed surface features which cause the tissue graft to have characteristics for a specific anatomical area. The modified tissue graft may comprise a medicated graft, such as by associating medicants with the surface features, or by associating a second graft or layer with a modified base tissue graft layer, where medicants are associated with the second graft or layer. The tissue graft may be modified by pressing a specially configured template or die, such as having blades thereon, into the tissue graft, such as to create a pattern of partial depth cuts.

公开(公告)号：US20240238480A1

公开(公告)日：2024-07-18

申请号：US18617246

申请日：2024-03-26

申请人： Tulavi Therapeutics, Inc. ,  Incept, LLC

发明人： Corinne BRIGHT ,  Yong REN ,  Kenneth M. Martin

IPC分类号： A61L27/26 ,  A61B17/00 ,  A61B17/11 ,  A61F2/00 ,  A61F2/02 ,  A61K9/00 ,  A61L27/18 ,  A61L27/52 ,  A61L31/14

CPC分类号： A61L27/26 ,  A61B17/1128 ,  A61F2/00 ,  A61F2/02 ,  A61K9/0004 ,  A61L27/18 ,  A61L27/52 ,  A61L31/14 ,  A61B2017/00526 ,  A61F2210/00 ,  A61F2210/008 ,  A61F2240/00 ,  A61F2240/001 ,  A61F2250/00 ,  A61L2400/06 ,  A61L2430/32

摘要： Disclosed are methods, devices and materials for the in situ formation of a nerve cap and/or a nerve wrap to inhibit neuroma formation following planned or traumatic nerve injury. The method includes the steps of identifying a severed end of a nerve, and positioning the severed end into a cavity defined by a form. A transformable media is introduced into the form cavity to surround the severed end. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the severed end. The media may be a hydrogel, and the transformation may produce a synthetic crosslinked hydrogel protective barrier. The media may include at least one anti-regeneration agent to inhibit nerve regrowth.

公开(公告)号：US20240229314A1

公开(公告)日：2024-07-11

申请号：US18386693

申请日：2023-11-03

申请人： ZEUS COMPANY INC.

发明人： Robert L. Ballard ,  Bruce L. Anneaux ,  Joshua L. Manasco ,  David P. Garner ,  Ping Hao

IPC分类号： D04H1/728 ,  A61F2/02 ,  B01D39/04 ,  B01D39/16 ,  B01D71/32 ,  D04H1/4326

CPC分类号： D04H1/728 ,  A61F2/02 ,  B01D39/04 ,  B01D39/1623 ,  B01D71/32 ,  D04H1/4326 ,  B01D2239/0631 ,  B01D2239/0654 ,  B01D2239/1233 ,  B01D2323/39 ,  Y10T428/24967 ,  Y10T428/24992

摘要： Espun material may function as a filtration medium or be put to other uses. The espun material may comprise espun poly(tetrafluoroethylene) (espun PTFE). One or more layers of the espun material may be included. The properties of the espun material can be tailored. For example, a gradient fabric may include espun PTFE. The gradient fabric may include two or more layers of espun PTFE.

公开(公告)号：US20240207588A1

公开(公告)日：2024-06-27

申请号：US18288099

申请日：2022-04-25

申请人： SANOFI

发明人： Lionel Vedrine ,  Christina Laskar ,  Pradeep Dhal ,  Craig Harvey Nelson ,  Mark Robson Humphries ,  Carys Eleri Lee ,  Nicholas Oliver Harding

IPC分类号： A61M37/00 ,  A61F2/02

CPC分类号： A61M37/0015 ,  A61F2/022 ,  A61M2037/0023 ,  A61M2207/10

摘要： A method of manufacturing a therapeutic device includes forming a container wall that is sized to contain multiple cells capable of producing a therapeutic agent within an interior region of the container wall. The method further includes exposing the container wall to a solvent to remove material from the container wall to define first pores along an interior portion of the container wall and second pores along an exterior portion of the container wall. The first pores have a first average size that (i) allows passage of the therapeutic agent through the first pores and (ii) prevents passage of immune cells through the first pores. The second pores have a second average size that is larger than the first average size, and the second pores are sized to promote vascularization along the exterior portion.

公开(公告)号：US20240197464A1

公开(公告)日：2024-06-20

申请号：US18288087

申请日：2022-04-25

申请人： Sanofi

发明人： Lionel Vedrine ,  Christina Laskar ,  Pradeep Dhal ,  Craig Harvey Nelson ,  Mark Robson Humphries ,  Carys Eleri Lee ,  Nicholas Oliver Harding

IPC分类号： A61F2/02 ,  A61L27/38 ,  A61L27/54 ,  A61L27/56

CPC分类号： A61F2/022 ,  A61L27/3804 ,  A61L27/54 ,  A61L27/56 ,  A61F2230/0069 ,  A61L2300/414

摘要： An implantable device for providing a therapeutic agent includes a container configured to contain multiple cells capable of producing the therapeutic agent within an interior region of the container. The container defines first pores defined by an interior wall portion of the container and second pores defined by an exterior wall portion of the container. The first pores have a first average size that (i) allows passage of the therapeutic agent and oxygen through the first pores and (ii) prevents passage of immune cells through the first pores. The second pores have a second average size that is larger than the first average size, and the second pores are sized to promote vascularization and oxygen transfer along the exterior wall portion.

公开(公告)号：US11977817B2

公开(公告)日：2024-05-07

申请号：US17174448

申请日：2021-02-12

申请人： Smith and Nephew, Inc.

发明人： Brian W. McKinnon ,  Ruxandra C. Marinescu Tanasoca ,  Randy C. Winebarger ,  William L. Bowers, Jr. ,  James B. Wiebe, III ,  Nathaniel M. Lenz ,  Zachary C. Wilkinson ,  Sean M. Haddock ,  Ryan L Landon

IPC分类号： G06F30/00 ,  A61B34/10 ,  A61F2/02 ,  A61B17/56

CPC分类号： G06F30/00 ,  A61B34/10 ,  A61F2/02 ,  A61B2017/568 ,  A61B2034/104 ,  A61B2034/105 ,  A61B2034/108

摘要： A system and method for pre-operatively optimizing a fit of an orthopaedic implant relative to a particular individuals anatomy is provided. The method includes: receiving information including a three-dimensional anatomic model of the individuals anatomy; computing a periphery of a simulated resection portion of the anatomic model without reference to any abnormal morphology; identifying a preliminary size for an orthopaedic implant component for use on the simulated resection surface; initially positioning the orthopaedic implant model relative to the simulated resection portion; generating random point sets around the peripheries of the simulated resection portion and the orthopaedic implant model; utilizing a position optimizer to determine whether the position of the orthopaedic implant periphery relative to the simulated resection portion periphery is optimal; determining whether the selected orthopaedic implant model results in overhang; and verifying the position of the orthopaedic implant and/or the size of the orthopaedic implant.

公开(公告)号：US11963862B2

公开(公告)日：2024-04-23

申请号：US16546951

申请日：2019-08-21

申请人： Boston Scientific Scimed Inc.

发明人： Aiden Flanagan ,  Matthew McEvaddy ,  Martin L. Fawdry

IPC分类号： A61F2/02 ,  A61L31/14 ,  A61L31/16 ,  A61M31/00 ,  A61M39/02 ,  C12N5/071

CPC分类号： A61F2/022 ,  A61L31/146 ,  A61L31/16 ,  A61M31/002 ,  A61M39/0208 ,  A61M39/0247 ,  A61L31/148 ,  A61M2039/0282 ,  C12N5/0677

摘要： A cell encapsulation device for implantation in a body includes one or more cell encapsulation layers, each of the one or more cell encapsulation layers including at least one membrane and a guide tube. The at least one membrane is semipermeable. The least one membrane forms a chamber for encapsulating cells and at least one access port through the at least one membrane. The guide tube extends into the chamber from the at least one access port. The guide tube includes a porous wall along at least a portion of its length. The guide tube is capable of guiding movement of a catheter within the chamber.